Integrated Investment Consultants LLC Has $3.03 Million Stake in Merck & Co., Inc. $MRK

Integrated Investment Consultants LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 53.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 28,816 shares of the company’s stock after purchasing an additional 10,087 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Merck & Co., Inc. were worth $3,033,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Chesapeake Wealth Management grew its holdings in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after purchasing an additional 87 shares during the last quarter. Westside Investment Management Inc. grew its position in shares of Merck & Co., Inc. by 3.1% in the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after purchasing an additional 93 shares during the last quarter. Valued Wealth Advisors LLC grew its position in shares of Merck & Co., Inc. by 26.9% in the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after purchasing an additional 94 shares during the last quarter. Payne Capital LLC increased its stake in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock worth $1,120,000 after purchasing an additional 97 shares during the period. Finally, Center for Financial Planning Inc. lifted its position in shares of Merck & Co., Inc. by 0.8% during the 4th quarter. Center for Financial Planning Inc. now owns 12,110 shares of the company’s stock worth $1,275,000 after purchasing an additional 98 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 0.0%

NYSE MRK opened at $111.36 on Monday. The firm has a market cap of $275.03 billion, a PE ratio of 31.37, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18. Merck & Co., Inc. has a one year low of $74.37 and a one year high of $125.14. The stock’s 50 day simple moving average is $116.00 and its 200 day simple moving average is $109.36. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.Merck & Co., Inc.’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRK has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. TD Cowen increased their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.